Blog
RSS FeedPosted by Michael Wonder on 29 Sep 2016
More on NICE recommendation of Imlygic
28 September 2016 - More on NICE's guidance on the use of talimogene laherparepvec for unresectable metastatic melanoma. ...
Posted by Michael Wonder on 29 Sep 2016
NICE rejects LIlly's Portrazza
28 September 2016 - NICE is not in favour of the use of Portrazza on the NHS. ...
Posted by Michael Wonder on 28 Sep 2016
NICE recommends the reimbursement of Imlygic
28 September 2016 - NICE has recommended the relimbursement of Amgen's new cellular therapy for patients with malignant melanoma. ...
Posted by Michael Wonder on 28 Sep 2016
Agenda for the 5 October 2016 TC meeting
28 September 2016 - HAS has posted the agenda for the next scheduled TC meeting. ...
Posted by Michael Wonder on 28 Sep 2016
Patients with BRVO, a sight threatening eye condition, now have first-line access to EYLEA (aflibercept solution for injection) on the NHS
28 September 2016 - Bayer is pleased to announce that NICE has made the final recommendation for aflibercept for the treatment ...
Posted by Michael Wonder on 28 Sep 2016
Decision to not accept any proposals for the insulin glargine request for proposals
28 September 2016 - PHARMAC has decided not accept any proposals for the supply of insulin glargine following consideration of responses ...
Posted by Michael Wonder on 27 Sep 2016
TC opinion on Lyxumia finally published
26 September 2016 - The Transparency Commission has published its opinion on Sanofi's GLP-1 analogue. ...
Posted by Michael Wonder on 27 Sep 2016
NICE sets out proposed technology assessment fees
18 September 2016 - NICE in the UK has been exploring the idea of charging the pharmaceutical industry for technology ...
Posted by Michael Wonder on 27 Sep 2016
Why is getting the abortion pill to women such a complicated thing?
27 September 2016 - Already the victims of Health Canada’s glacial bureaucracy, and of its paternalistic view of their ability to ...
Posted by Michael Wonder on 26 Sep 2016
Nivolumab plus ipilimumab in melanoma: added benefit in certain patients
15 September 2016 - Survival advantage in BRAF V600 wild type tumour depends on gender / severe side effects more common. ...
Posted by Michael Wonder on 26 Sep 2016
Most provincial drug plans won’t cover abortion pills in Canada
26 September 2016 - When the gold standard in medical abortion drugs finally becomes available in Canada later this year, the ...
Posted by Michael Wonder on 25 Sep 2016
Families to save hundreds of dollars under PBS changes
26 September 2016 - Australians will be able to save hundreds of dollars a year from October 1 as prices are ...
Posted by Michael Wonder on 24 Sep 2016
CADTH publishes final recommendation for Lenvima (lenvatinib mesylate)
20 September 2016 - CADTH has posted its final outcome for Eisai's Lenvima. ...
Posted by Michael Wonder on 23 Sep 2016
NICE says yes to another hepatitis C drug
23 September 2016 - A new drug which effectively treats more genotypes of hepatitis C has been recommended for use in ...
Posted by Michael Wonder on 23 Sep 2016
UK audit shows infliximab biosimilars are safe, effective, and cheap
22 September 2016 - Infliximab “biosimilars”—biological therapies engineered to work in the same way as the monoclonal antibody drug infliximab (Remicade)—are ...